You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Endometriosis Drugs Market Research Report 2021 Professional Edition

Market Analysis and Insights: Global Endometriosis Drugs Market
The research report studies the Endometriosis Drugs market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Endometriosis Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Endometriosis Drugs Scope and Segment
The global Endometriosis Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Endometriosis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Hormonal Therapy
Add-back Medication
Progestogens
Chinese Herbs
by Application, this report covers the following segments
Hospitals
Clinics
Research Institutes
Global Endometriosis Drugs market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Endometriosis Drugs key players in this market include:
AbbVie
Astellas Pharma
AstraZeneca
Debiopharm Group
Evotec
Kissei Pharmaceutical
Neurocrine Biosciences
ObsEva
Pfizer
Repros Therapeutics
Roivant Sciences
Takeda Pharmaceutical Company
ValiRx
1 Market Overview of Endometriosis Drugs
1.1 Endometriosis Drugs Market Overview
1.1.1 Endometriosis Drugs Product Scope
1.1.2 Endometriosis Drugs Market Status and Outlook
1.2 Global Endometriosis Drugs Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Endometriosis Drugs Market Size by Region (2016-2027)
1.4 Global Endometriosis Drugs Historic Market Size by Region (2016-2021)
1.5 Global Endometriosis Drugs Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Endometriosis Drugs Market Size (2016-2027)
1.6.1 North America Endometriosis Drugs Market Size (2016-2027)
1.6.2 Europe Endometriosis Drugs Market Size (2016-2027)
1.6.3 Asia-Pacific Endometriosis Drugs Market Size (2016-2027)
1.6.4 Latin America Endometriosis Drugs Market Size (2016-2027)
1.6.5 Middle East & Africa Endometriosis Drugs Market Size (2016-2027)

2 Endometriosis Drugs Market Overview by Type
2.1 Global Endometriosis Drugs Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Endometriosis Drugs Historic Market Size by Type (2016-2021)
2.3 Global Endometriosis Drugs Forecasted Market Size by Type (2022-2027)
2.4 Hormonal Therapy
2.5 Add-back Medication
2.6 Progestogens
2.7 Chinese Herbs

3 Endometriosis Drugs Market Overview by Application
3.1 Global Endometriosis Drugs Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Endometriosis Drugs Historic Market Size by Application (2016-2021)
3.3 Global Endometriosis Drugs Forecasted Market Size by Application (2022-2027)
3.4 Hospitals
3.5 Clinics
3.6 Research Institutes

4 Endometriosis Drugs Competition Analysis by Players
4.1 Global Endometriosis Drugs Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Endometriosis Drugs as of 2020)
4.3 Date of Key Players Enter into Endometriosis Drugs Market
4.4 Global Top Players Endometriosis Drugs Headquarters and Area Served
4.5 Key Players Endometriosis Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Endometriosis Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data
5.1 AbbVie
5.1.1 AbbVie Profile
5.1.2 AbbVie Main Business
5.1.3 AbbVie Endometriosis Drugs Products, Services and Solutions
5.1.4 AbbVie Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.1.5 AbbVie Recent Developments
5.2 Astellas Pharma
5.2.1 Astellas Pharma Profile
5.2.2 Astellas Pharma Main Business
5.2.3 Astellas Pharma Endometriosis Drugs Products, Services and Solutions
5.2.4 Astellas Pharma Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.2.5 Astellas Pharma Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Endometriosis Drugs Products, Services and Solutions
5.3.4 AstraZeneca Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.3.5 Debiopharm Group Recent Developments
5.4 Debiopharm Group
5.4.1 Debiopharm Group Profile
5.4.2 Debiopharm Group Main Business
5.4.3 Debiopharm Group Endometriosis Drugs Products, Services and Solutions
5.4.4 Debiopharm Group Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.4.5 Debiopharm Group Recent Developments
5.5 Evotec
5.5.1 Evotec Profile
5.5.2 Evotec Main Business
5.5.3 Evotec Endometriosis Drugs Products, Services and Solutions
5.5.4 Evotec Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.5.5 Evotec Recent Developments
5.6 Kissei Pharmaceutical
5.6.1 Kissei Pharmaceutical Profile
5.6.2 Kissei Pharmaceutical Main Business
5.6.3 Kissei Pharmaceutical Endometriosis Drugs Products, Services and Solutions
5.6.4 Kissei Pharmaceutical Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.6.5 Kissei Pharmaceutical Recent Developments
5.7 Neurocrine Biosciences
5.7.1 Neurocrine Biosciences Profile
5.7.2 Neurocrine Biosciences Main Business
5.7.3 Neurocrine Biosciences Endometriosis Drugs Products, Services and Solutions
5.7.4 Neurocrine Biosciences Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.7.5 Neurocrine Biosciences Recent Developments
5.8 ObsEva
5.8.1 ObsEva Profile
5.8.2 ObsEva Main Business
5.8.3 ObsEva Endometriosis Drugs Products, Services and Solutions
5.8.4 ObsEva Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.8.5 ObsEva Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Endometriosis Drugs Products, Services and Solutions
5.9.4 Pfizer Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.9.5 Pfizer Recent Developments
5.10 Repros Therapeutics
5.10.1 Repros Therapeutics Profile
5.10.2 Repros Therapeutics Main Business
5.10.3 Repros Therapeutics Endometriosis Drugs Products, Services and Solutions
5.10.4 Repros Therapeutics Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.10.5 Repros Therapeutics Recent Developments
5.11 Roivant Sciences
5.11.1 Roivant Sciences Profile
5.11.2 Roivant Sciences Main Business
5.11.3 Roivant Sciences Endometriosis Drugs Products, Services and Solutions
5.11.4 Roivant Sciences Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.11.5 Roivant Sciences Recent Developments
5.12 Takeda Pharmaceutical Company
5.12.1 Takeda Pharmaceutical Company Profile
5.12.2 Takeda Pharmaceutical Company Main Business
5.12.3 Takeda Pharmaceutical Company Endometriosis Drugs Products, Services and Solutions
5.12.4 Takeda Pharmaceutical Company Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.12.5 Takeda Pharmaceutical Company Recent Developments
5.13 ValiRx
5.13.1 ValiRx Profile
5.13.2 ValiRx Main Business
5.13.3 ValiRx Endometriosis Drugs Products, Services and Solutions
5.13.4 ValiRx Endometriosis Drugs Revenue (US$ Million) & (2016-2021)
5.13.5 ValiRx Recent Developments

6 North America
6.1 North America Endometriosis Drugs Market Size by Country (2016-2027)
6.2 United States
6.3 Canada

7 Europe
7.1 Europe Endometriosis Drugs Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe

8 Asia-Pacific
8.1 Asia-Pacific Endometriosis Drugs Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific

9 Latin America
9.1 Latin America Endometriosis Drugs Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America

10 Middle East & Africa
10.1 Middle East & Africa Endometriosis Drugs Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa

11 Endometriosis Drugs Market Dynamics
11.1 Endometriosis Drugs Industry Trends
11.2 Endometriosis Drugs Market Drivers
11.3 Endometriosis Drugs Market Challenges
11.4 Endometriosis Drugs Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • FORMAT: PDF
  • PUBLISHED DATE: Jun, 2021
  • NO OF PAGES: 140